bispecific therapeutics

Oncology

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

News

Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.